EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Higher diversity of anti-diabetic therapy is associated with lower risk of major adverse kidney events in diabetes

Shu-Ping Zhang, Ting-Ting Huang, Qing-Lian Zeng, Wen-Jin Luo, Yun-Jie Xiong, Chuan Peng, Fei Lian, Qing-Feng Cheng, Zhi-Hong Wang, Wei Huang, Yong Xu, Qi-Fu Li, Shu-Min Yang, Xiang-Jun Chen, Jin-Bo Hu, Xi-Yue Li

World Journal of Diabetes · 2026-11-15 · 17 (11)

DOI: 10.4239/wjd.123922 ↗
AbstractBibliografische Angaben

Abstract

BACKGROUND Diverse anti-diabetic combinations are widely indicated for uncontrolled hyperglycemia to avoid microvascular complications including kidney injury. Current studies on combination therapy’s long-term renal risk yield conflicting results, largely limited by inadequate confounder adjustment. We hypothesized combination anti-diabetic therapy reduces major adverse kidney events (MAKE) vs monotherapy in diabetic patients. AIM To investigate the association between the diversity of anti-diabetic therapy and long-term renal outcomes in patients with diabetes. METHODS We included participants with diabetes and glycated hemoglobin A1c ≥ 7% from the UK Biobank (UKB) and Chongqing Diabetes Registry (CDR). Using a target trial emulation design, we compared the effect of monotherapy vs combination therapy on MAKE (composite of end-stage renal disease and kidney disease death). Intention-to-treat and per-protocol analyses were conducted in UKB and CDR, respectively. RESULTS Propensity score matching identified 3475 monotherapy-combination therapy pairs in the UKB and 261-808 pairs in the CDR. Over median 13.4 years in UKB, combination therapy was associated with lower MAKE risk vs monotherapy (hazard ratio 0.65; 95% confidence interval: 0.46-0.92). In CDR, when compared with patients who maintained monotherapy, patients who maintained combination therapy had significantly lower risk of MAKE (hazard ratio 0.24; 95% confidence interval: 0.11-0.55) although their glycated hemoglobin A1c level was similar at baseline and during follow up. Sensitivity analyses excluding renoprotective medications showed consistent results. CONCLUSION Beyond glycemic control, a greater diversity of anti-diabetic therapy is associated with lower risk of MAKE in diabetic patients.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →